12th Feb 2007 14:00
GlaxoSmithKline PLC12 February 2007 Issued - 12th February 2007, London GLAXOSMITHKLINE PLC ANNOUNCES CHANGE TO THE BOARD OF DIRECTORS GlaxoSmithKline plc (GSK) announces that Dr Stephanie Burns has been appointedas a Non-Executive Director and will join the Board of the Company withimmediate effect. Dr Burns is Chairman, President and Chief Executive Officer of Dow CorningCorporation. An expert in organic chemistry, Dr Burns is also a member of theAmerican Chemical Society and sits on the executive committee of the Society ofChemical Industry. In commenting on the new appointment, Sir Christopher Gent, Chairman of GSK,said: "I am delighted that Stephanie has agreed to join the GSK Board. As arecognised business leader of a global organisation, together with her strongscientific background and staunch advocacy for science education, Stephanie willbring a wealth of experience to the Board." Dr Burns' biographical details are given below together with a table showing themembership of the Board and its Committees with effect from 12th February 2007. Simon BicknellCompany Secretary 12th February 2007 NOTES The Board has determined that Dr Burns is independent in accordance with theCombined Code on Corporate Governance. BIOGRAPHICAL DETAILS Dr Stephanie Burns Age 51. Dr Burns is Chairman, president and chief executive officer of DowCorning. She joined Dow Corning in 1983 as a researcher working on water basedand high temperature elastomers. She became director of Women's Health in 1994and subsequently moved into corporate management becoming Science and TechnologyDirector for Europe in 1997. She was first elected to Dow Corning's Board ofDirectors in December 2000, she was then elected president and chief executiveofficer in February 2003, Chief Operating Officer in January 2004 and Chairmanin January 2006. Dr Burns holds a Ph.D. in organic chemistry, with an organosilicon specialty,from Iowa State University. She completed her post-doctoral studies at theUniversite Montpellier, Sciences et Techniques du Languedoc, France. She is a board member of the American Chemical Society and The Conference Boardand sits on the executive committee of the Society of Chemical Industry. Shehas also serves on the Michigan Molecular Institute. BOARD AND COMMITTEE MEMBERSHIP WITH EFFECT FROM 12TH FEBRUARY 2007 Sir Christopher Gent Chairman Sir Ian Prosser Senior Independent Non-Executive Director Dr J-P Garnier Chief Executive Officer Mr J S Heslop Chief Financial Officer Dr Moncef Slaoui Executive Director, Chairman, Research & Development Dr Stephanie Burns Independent Non-Executive Director Mr H Lawrence Culp Independent Non-Executive Director Sir Crispin Davis Independent Non-Executive Director Sir Deryck Maughan Independent Non-Executive Director Dr Daniel Podolsky Independent Non-Executive Director Dr Ronaldo Schmitz Independent Non-Executive Director Mr Tom de Swaan Independent Non Executive Director Sir Robert Wilson Independent Non-Executive Director Board Committee Committee Chairman Members Audit Mr Tom de Swaan Sir Deryck Maughan Dr Daniel Podolsky Sir Ian Prosser Dr Ronaldo Schmitz Sir Robert Wilson Remuneration Sir Robert Wilson Mr H Lawrence Culp Sir Crispin Davis Sir Christopher Gent Dr Ronaldo Schmitz Nominations Sir Christopher Gent Sir Ian Prosser Dr Ronaldo Schmitz Corporate Responsibility Sir Christopher Gent Sir Ian Prosser Mr Tom de Swaan Dr Daniel Podolsky GlaxoSmithKline enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 Alice Hunt (020) 8047 5502 Gwenan White (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst/Investor enquiries: Anita Kidgell (020) 8047 5542 David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline